Indianapolis – Lilly is committed to meeting the needs of people affected by diabetes and obesity with treatment options that change the way healthcare providers can treat these diseases and offer breakthroughs for patients. The development and approvals of Mounjaro® and Zepbound® demonstrate our continued commitment to this mission. Patient safety is Lilly’s top priority, and we actively monitor, evaluate, and report …
INDIANAPOLIS – Detailed results from SURMOUNT-4, which showed Zepbound™ (tirzepatide) injection achieved superior mean percent change in body weight compared to placebo in adults with obesity or overweight with weight-related comorbidities, excluding type 2 diabetes, were published in The Journal of the American Medical Association (JAMA). Zepbound met the primary endpoint of mean percent change in body weight, and all key secondary endpoints …
